Literature DB >> 2385332

Behavioural and pharmacokinetic studies on nicotine, cytisine and lobeline.

C Reavill1, B Walther, I P Stolerman, B Testa.   

Abstract

Previous work has suggested that cytisine and lobeline are of low potency in producing nicotine-like behavioural effects, despite having some nicotine-like peripheral effects and potently inhibiting the binding of tritiated nicotine to the brain of the rat. Rats were trained to discriminate nicotine from saline in a two-bar operant conditioning procedure with food reinforcement. It was confirmed that cytisine had a nicotine-like discriminative effect, but it was much less potent than nicotine itself. Lobeline failed to produce a nicotine-like discriminative effect, even at doses that greatly reduced overall rates of responding. Neither drug attenuated discriminative responses to nicotine. The concentrations of drugs in plasma and brain were determined by HPLC in rats of the same sex, strain and age as those used in the behavioural experiments. The rank order of the ratios of concentrations in brain to plasma was lobeline greater than nicotine greater than cytisine, which was directly proportional to their lipophilicity determined by reversed-phase HPLC. Based on the concentrations in brain and known affinities for high-affinity nicotine binding sites, in vivo tests should show cytisine to be slightly more potent than nicotine and lobeline to have nicotine effects in the doses used. These predictions were not fulfilled and thus, the behavioural effects of cytisine and lobeline cannot be correlated with their effects at the binding site for tritiated nicotine. Since pharmacokinetic factors do not account for this discrepancy, a pharmacodynamic explanation will be necessary.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2385332     DOI: 10.1016/0028-3908(90)90022-j

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  33 in total

1.  Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence.

Authors:  H Rollema; A Shrikhande; K M Ward; F D Tingley; J W Coe; B T O'Neill; E Tseng; E Q Wang; R J Mather; R S Hurst; K E Williams; M de Vries; T Cremers; S Bertrand; D Bertrand
Journal:  Br J Pharmacol       Date:  2010-03-22       Impact factor: 8.739

2.  Synthesis and pharmacological evaluation of novel 9- and 10-substituted cytisine derivatives. Nicotinic ligands of enhanced subtype selectivity.

Authors:  Sheela K Chellappan; Yingxian Xiao; Werner Tueckmantel; Kenneth J Kellar; Alan P Kozikowski
Journal:  J Med Chem       Date:  2006-05-04       Impact factor: 7.446

3.  Dopaminergic and cholinergic involvement in the discriminative stimulus effects of nicotine and cocaine in rats.

Authors:  Rajeev I Desai; David J Barber; Philip Terry
Journal:  Psychopharmacology (Berl)       Date:  2003-04-09       Impact factor: 4.530

4.  Nicotinic receptor ligands reduce ethanol intake by high alcohol-drinking HAD-2 rats.

Authors:  Richard L Bell; Bill J A Eiler; Jason B Cook; Shafiqur Rahman
Journal:  Alcohol       Date:  2009-12       Impact factor: 2.405

5.  Multiple nicotine training doses in mice as a basis for differentiating the effects of smoking cessation aids.

Authors:  Colin S Cunningham; Lance R McMahon
Journal:  Psychopharmacology (Berl)       Date:  2013-03-14       Impact factor: 4.530

6.  Effects of nicotinic acetylcholine receptor ligands on behavioral vigilance in rats.

Authors:  J Turchi; L A Holley; M Sarter
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

7.  Effects of the nicotinic receptor partial agonists varenicline and cytisine on the discriminative stimulus effects of nicotine in rats.

Authors:  Mark G LeSage; David Shelley; Jason T Ross; F Ivy Carroll; William A Corrigall
Journal:  Pharmacol Biochem Behav       Date:  2008-09-09       Impact factor: 3.533

8.  Release of [3H]-noradrenaline from rat hippocampal synaptosomes by nicotine: mediation by different nicotinic receptor subtypes from striatal [3H]-dopamine release.

Authors:  P B Clarke; M Reuben
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

9.  Varenicline for smoking cessation: efficacy, safety, and treatment recommendations.

Authors:  Jon O Ebbert; Kirk D Wyatt; J Taylor Hays; Eric W Klee; Richard D Hurt
Journal:  Patient Prefer Adherence       Date:  2010-10-05       Impact factor: 2.711

Review 10.  Smoking cessation therapy with varenicline.

Authors:  Uma M Mohanasundaram; Rajinder Chitkara; Ganesh Krishna
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.